查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1367854

全球癌症 API 市场 - 预测（~2030 年）

Global Cancer API Market Research Report - Forecast to 2030
出版日期: | 出版商: Market Research Future | 英文 100 Pages | 订单完成后即时交付

价格

在研究期间，全球癌症 API 市场规模预计将以 7.10% 的复合年增长率健康成长。 在预测期内，由于全球范围内存在大量机遇，癌症 API 市场份额预计将大幅增长。

本报告研究分析了全球癌症原料药市场，提供市场动态、区域和细分市场分析、公司简介等。

目录

第一章简介

第二章研究方法

第三章市场动态

  • 简介
  • 促进因素
    • 对新开发的小分子药物的需求不断增加
    • 外包成长趋势
    • 发展中国家製药业的成长
    • 快速生长的肺癌发生率不断上升
    • 报销和不断增长的健康保险
  • 抑制因素
    • 欧洲紧缩政策
    • 目前治疗的疗效、治癒率和副作用不足
    • 抗癌药物专利语言
  • 机会
    • API 製造的发展

第四章市场因素分析

  • 价值/供应链分析
    • 研究与开发
    • 原料
    • 製造商
    • 卖家
    • 客户
    • 消费者
  • 波特五力分析

第五章全球癌症 API 市场

  • NIBS
    • TINIB
    • RAFENIBS
    • 其他
  • IBS
    • PARIBS
    • LISIBS
    • DEGIBS
    • CICLIBS

第六章竞争态势

  • 简介
  • 公司股票分析

第七章公司简介

  • ABBVIE
  • PFIZER INC.
  • BOEHRINGER INGELHEIM
  • ASTRAZENECA
  • NOVARTIS AG
  • F. HOFFMANN-LA ROCHE AG
  • BAYER AG
  • BRISTOL-MYERS SQUIBB
  • EISAI LTD
Product Code: MRFR/Pharma/4782-CR

Market Overview

The Cancer API Market is expected to register a healthy CAGR of 7.10% during the review period. Because there are so many opportunities worldwide during the projected period, the market share for cancer APIs is anticipated to experience significant growth. The development of molecular pharmaceuticals, the rising number of cancer cases, the trend toward offshore pharmaceutical producers, and the introduction of fresh active pharmaceutical ingredients (API) are the factors that are driving demand in the market. Additionally, the construction of a smarter, healthier infrastructure that incorporates cancer APIs is being facilitated by the global economies. Although there are many prospects on the horizon, there are also many market challenges. Therefore, the manufacturers are shifting their attention to natural substances that are minimizing adverse effects to create worldwide acceptance for cancer APIs.

The overall expansion of the cancer API market is being adversely affected by the API sector's downturn. The first priority is to get the candidates into clinical trials, and with the aid of the developers, a moving shift is also made to secure manufacturing capacity. Along with government assistance for investment in the research and development sector, there are numerous agreements with CDMOs. Additionally, this will aid the producers in recouping their pandemic-related losses.

Segment Overview

The cancer API market report discusses the market segments namely type and region.

For patients with cancer, the type section also comprises peptides, small molecules, and oligonucleotides in addition to carbohydrate and steroidal medications.

Regional Analysis

The USA and Canadian oncology active pharmaceutical ingredients (APIs) markets make up the North American area. The American healthcare system is becoming an effective one for delivering healthcare services that includes cutting-edge infrastructure. The price for the same is, nevertheless, extremely considerable. To oversee the nation's healthcare system, the US government has chosen to enact regulations and roll out insurance programs. Additionally, US businesses are widely choosing cost-effective solutions to lessen the strain of healthcare development.

Germany's healthcare industry is expanding. The German healthcare system, which is regarded as one of the most successful in the world, is mostly to blame for this since it offers a greater fund quantum. Regional technical development is increasing, and market participants are becoming more globally present. Additionally, chronic diseases are becoming more prevalent among people, particularly the elderly population, in the German areas. The nation is heavily spending in research, development, and infrastructure for better treatments and infrastructure for curing various types of cancer. By the decade's end in 2031, there is a perfect potential for the market share of cancer APIs to increase in this area.

Major Players

The key competitors in cancer API market are Exelixis Inc, TESARO, Inc, Puma Biotech, Eli Lilly & Company, Pfizer Inc, Eisai Ltd, Incyte Corporation, Hoffman La Roche, Ariad Pharmaceuticals (Takeda), Bristol-Myers Squibb, Celgene, Gilead Lifesciences, AbbVie Inc., AstraZeneca plc, Novartis AG, Bayer AG, and Clovis Oncology.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 DEFINITION 16
  • 1.2 SCOPE OF THE STUDY 16
  • 1.3 LIST OF ASSUMPTIONS 17
  • 1.4 MARKET STRUCTURE 17

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH PROCESS 19
  • 2.2 PRIMARY RESEARCH 20
  • 2.3 SECONDARY RESEARCH 21
  • 2.4 FORECAST MODEL 22

3 MARKET DYNAMICS

  • 3.1 INTRODUCTION 24
  • 3.2 DRIVERS 25
    • 3.2.1 GROWING DEMAND FOR NEWLY DEVELOPED SMALL MOLECULES DRUGS 25
    • 3.2.2 GROWING TREND OF OUTSOURCING 25
    • 3.2.3 GROWING PHARMACEUTICAL INDUSTRY IN DEVELOPING NATIONS 25
    • 3.2.4 RISING RATES OF FAST GROWING LUNG CANCER 25
    • 3.2.5 REIMBURSEMENTS AND GROWING HEALTH INSURANCE 25
  • 3.3 RESTRAINTS 26
    • 3.3.1 AUSTERITY MEASURES IN EUROPE 26
    • 3.3.2 POOR EFFICACY, CURE RATES, AND SIDE EFFECTS OF PRESENT TREATMENTS 26
    • 3.3.3 LOSS OF PATENTS OF CANCER DRUGS 26
  • 3.4 OPPORTUNITIES 26
    • 3.4.1 DEVELOPMENT IN API MANUFACTURING 26

4 MARKET FACTOR ANALYSIS

  • 4.1 VALUE/SUPPLY CHAIN ANALYSIS 28
    • 4.1.1 RESEARCH & DEVELOPMENT 28
    • 4.1.2 RAW MATERIAL 28
    • 4.1.3 MANUFACTURER 28
    • 4.1.4 DISTRIBUTOR 29
    • 4.1.5 CUSTOMER 29
    • 4.1.6 CONSUMER 29
  • 4.2 PORTER'S FIVE FORCE ANALYSIS 30
    • 4.2.1 THREAT FROM A NEW ENTRANT 31
    • 4.2.2 BARGAINING POWER OF BUYER 31
    • 4.2.3 BARGAINING POWER OF SUPPLIER 31
    • 4.2.4 THREAT FROM SUBSTITUTE 32
    • 4.2.5 RIVALRY 32

5 GLOBAL CANCER API MARKET

  • 5.1 NIBS 34
    • 5.1.1 TINIB 34
      • 5.1.1.1 PONATINIB 34
      • 5.1.1.1.1 OVERVIEW 34
      • 5.1.1.1.2 COMPANY 34
      • 5.1.1.1.3 MECHANISM OF ACTION 34
      • 5.1.1.2 BRIGATINIB 35
      • 5.1.1.2.1 OVERVIEW 35
      • 5.1.1.2.2 COMPANY 35
      • 5.1.1.2.3 MECHANISM OF ACTION 35
      • 5.1.1.3 RUXOLITINIB 36
      • 5.1.1.3.1 OVERVIEW 36
      • 5.1.1.3.2 COMPANY 36
      • 5.1.1.3.3 MECHANISM OF ACTION 36
      • 5.1.1.4 ERLOTINIB 37
      • 5.1.1.4.1 OVERVIEW 37
      • 5.1.1.4.2 COMPANY 37
      • 5.1.1.4.3 MECHANISM OF ACTION 37
      • 5.1.1.5 ALECTINIB 38
      • 5.1.1.5.1 OVERVIEW 38
      • 5.1.1.5.2 COMPANY 38
      • 5.1.1.5.3 MECHANISM OF ACTION 38
      • 5.1.1.6 COBIMETINIB 39
      • 5.1.1.6.1 OVERVIEW 39
      • 5.1.1.6.2 COMPANY 39
      • 5.1.1.6.3 MECHANISM OF ACTION 39
      • 5.1.1.7 NERATINIB 40
      • 5.1.1.7.1 OVERVIEW 40
      • 5.1.1.7.2 COMPANY 40
      • 5.1.1.7.3 MECHANISM OF ACTION 40
      • 5.1.1.8 OSIMERTINIB 41
      • 5.1.1.8.1 OVERVIEW 41
      • 5.1.1.8.2 COMPANY 41
      • 5.1.1.8.3 MECHANISM OF ACTION 41
      • 5.1.1.9 ACALABRUTINIB 42
      • 5.1.1.9.1 OVERVIEW 42
      • 5.1.1.9.2 COMPANY 42
      • 5.1.1.9.3 MECHANISM OF ACTION 42
      • 5.1.1.10 BOSUTINIB 43
      • 5.1.1.10.1 OVERVIEW 43
      • 5.1.1.10.2 COMPANY 43
      • 5.1.1.10.3 MECHANISM OF ACTION 43
      • 5.1.1.11 CRIZOTINIB 44
      • 5.1.1.11.1 OVERVIEW 44
      • 5.1.1.11.2 COMPANY 44
      • 5.1.1.11.3 MECHANISM OF ACTION 44
      • 5.1.1.12 AXITINIB 45
      • 5.1.1.12.1 OVERVIEW 45
      • 5.1.1.12.2 COMPANY 45
      • 5.1.1.12.3 MECHANISM OF ACTION 45
      • 5.1.1.13 SUNITINIB 46
      • 5.1.1.13.1 OVERVIEW 46
      • 5.1.1.13.2 COMPANY 46
      • 5.1.1.13.3 MECHANISM OF ACTION 46
      • 5.1.1.14 CERITINIB 47
      • 5.1.1.14.1 OVERVIEW 47
      • 5.1.1.14.2 COMPANY 47
      • 5.1.1.14.3 MECHANISM OF ACTION 47
      • 5.1.1.15 IMATINIB 48
      • 5.1.1.15.1 OVERVIEW 48
      • 5.1.1.15.2 COMPANY 48
      • 5.1.1.15.3 MECHANISM OF ACTION 48
      • 5.1.1.16 LAPATINIB 49
      • 5.1.1.16.1 OVERVIEW 49
      • 5.1.1.16.2 COMPANY 49
      • 5.1.1.16.3 MECHANISM OF ACTION 49
      • 5.1.1.17 AFATINIB 50
      • 5.1.1.17.1 OVERVIEW 50
      • 5.1.1.17.2 COMPANY 50
      • 5.1.1.17.3 MECHANISM OF ACTION 50
      • 5.1.1.18 CABOZANTINIB 51
      • 5.1.1.18.1 OVERVIEW 51
      • 5.1.1.18.2 COMPANY 51
      • 5.1.1.18.3 MECHANISM OF ACTION 51
      • 5.1.1.19 DASATINIB 52
      • 5.1.1.19.1 OVERVIEW 52
      • 5.1.1.19.2 COMPANY 52
      • 5.1.1.19.3 MECHANISM OF ACTION 52
      • 5.1.1.20 IBRUTINIB 53
      • 5.1.1.20.1 OVERVIEW 53
      • 5.1.1.20.2 COMPANY 53
      • 5.1.1.20.3 MECHANISM OF ACTION 53
      • 5.1.1.21 LENVATINIB 54
      • 5.1.1.21.1 OVERVIEW 54
      • 5.1.1.21.2 COMPANY 54
      • 5.1.1.21.3 MECHANISM OF ACTION 54
      • 5.1.1.22 GEFITINIB 55
      • 5.1.1.22.1 OVERVIEW 55
      • 5.1.1.22.2 COMPANY 55
      • 5.1.1.22.3 MECHANISM OF ACTION 55
    • 5.1.2 RAFENIBS 56
      • 5.1.2.1 SORAFENIB 56
      • 5.1.2.1.1 OVERVIEW 56
      • 5.1.2.1.2 COMPANY 56
      • 5.1.2.1.3 MECHANISM OF ACTION 56
      • 5.1.2.2 REGORAFENIB 57
      • 5.1.2.2.1 OVERVIEW 57
      • 5.1.2.2.2 COMPANY 57
      • 5.1.2.2.3 MECHANISM OF ACTION 57
      • 5.1.2.3 VEMURAFENIB 58
      • 5.1.2.3.1 OVERVIEW 58
      • 5.1.2.3.2 COMPANY 58
      • 5.1.2.3.3 MECHANISM OF ACTION 58
    • 5.1.3 OTHER 59
      • 5.1.3.1 DABRAFENIB + TRAMETINIB 59
      • 5.1.3.1.1 DABRAFENIB 59
      • 5.1.3.1.1.1 OVERVIEW 59
      • 5.1.3.1.1.2 COMPANY 59
      • 5.1.3.1.1.3 MECHANISM OF ACTION 59
      • 5.1.3.1.2 TRAMETINIB 59
      • 5.1.3.1.2.1 OVERVIEW 59
      • 5.1.3.1.2.2 COMPANY 59
      • 5.1.3.1.2.3 MECHANISM OF ACTION 59
      • 5.1.3.2 ENASIDENIB 60
      • 5.1.3.2.1 OVERVIEW 60
      • 5.1.3.2.2 COMPANY 60
      • 5.1.3.2.3 MECHANISM OF ACTION 60
      • 5.1.3.3 VANDETANIB 61
      • 5.1.3.3.1 OVERVIEW 61
      • 5.1.3.3.2 COMPANY 61
      • 5.1.3.3.3 MECHANISM OF ACTION 61
  • 5.2 IBS 62
    • 5.2.1 PARIBS 62
      • 5.2.1.1 OLAPARIB 62
      • 5.2.1.1.1 OVERVIEW 62
      • 5.2.1.1.2 COMPANY 62
      • 5.2.1.1.3 MECHANISM OF ACTION 62
      • 5.2.1.2 RUCAPARIB 63
      • 5.2.1.2.1 OVERVIEW 63
      • 5.2.1.2.2 COMPANY 63
      • 5.2.1.2.3 MECHANISM OF ACTION 63
      • 5.2.1.3 NIRAPARIB 64
      • 5.2.1.3.1 OVERVIEW 64
      • 5.2.1.3.2 COMPANY 64
      • 5.2.1.3.3 MECHANISM OF ACTION 64
    • 5.2.2 LISIBS 65
      • 5.2.2.1 IDELALISIB 65
      • 5.2.2.1.1 OVERVIEW 65
      • 5.2.2.1.2 COMPANY 65
      • 5.2.2.1.3 MECHANISM OF ACTION 65
      • 5.2.2.2 COPANLISIB 65
      • 5.2.2.2.1 OVERVIEW 65
      • 5.2.2.2.2 COMPANY 65
      • 5.2.2.2.3 MECHANISM OF ACTION 65
    • 5.2.3 DEGIBS 66
      • 5.2.3.1 SONIDEGIB 66
      • 5.2.3.1.1 OVERVIEW 66
      • 5.2.3.1.2 COMPANY 66
      • 5.2.3.1.3 MECHANISM OF ACTION 66
      • 5.2.3.2 VISMODEGIB 66
      • 5.2.3.2.1 OVERVIEW 66
      • 5.2.3.2.2 COMPANY 66
      • 5.2.3.2.3 MECHANISM OF ACTION 66
    • 5.2.4 CICLIBS 67
      • 5.2.4.1 PALBOCICLIB 67
      • 5.2.4.1.1 OVERVIEW 67
      • 5.2.4.1.2 COMPANY 67
      • 5.2.4.1.3 MECHANISM OF ACTION 67
      • 5.2.4.2 RIBOCICLIB 68
      • 5.2.4.2.1 OVERVIEW 68
      • 5.2.4.2.2 COMPANY 68
      • 5.2.4.2.3 MECHANISM OF ACTION 68
      • 5.2.4.3 ABEMACICLIB 69
      • 5.2.4.3.1 OVERVIEW 69
      • 5.2.4.3.2 COMPANY 69
      • 5.2.4.3.3 MECHANISM OF ACTION 69

6 COMPETITIVE LANDSCAPE

  • 6.1 INTRODUCTION 71
  • 6.2 COMPANY SHARE ANALYSIS 71

7 COMPANY PROFILES

  • 7.1 ABBVIE 73
    • 7.1.1 COMPANY OVERVIEW 73
    • 7.1.2 FINANCIAL OVERVIEW 73
    • 7.1.3 PRODUCTS/SERVICES OFFERING 74
    • 7.1.4 KEY DEVELOPMENTS 74
    • 7.1.5 SWOT ANALYSIS 74
    • 7.1.6 KEY STRATEGY 74
  • 7.2 PFIZER INC. 75
    • 7.2.1 COMPANY OVERVIEW 75
    • 7.2.2 FINANCIAL OVERVIEW 75
    • 7.2.3 PRODUCTS/SERVICES OFFERING 76
    • 7.2.4 KEY DEVELOPMENTS 76
    • 7.2.5 SWOT ANALYSIS 77
    • 7.2.6 KEY STRATEGY 77
  • 7.3 BOEHRINGER INGELHEIM 78
    • 7.3.1 COMPANY OVERVIEW 78
    • 7.3.2 FINANCIAL OVERVIEW 78
    • 7.3.3 PRODUCTS/SERVICES OFFERING 78
    • 7.3.4 KEY DEVELOPMENTS 79
    • 7.3.5 SWOT ANALYSIS 79
    • 7.3.6 KEY STRATEGY 79
  • 7.4 ASTRAZENECA 80
    • 7.4.1 COMPANY OVERVIEW 80
    • 7.4.2 FINANCIAL OVERVIEW 80
    • 7.4.3 PRODUCTS/SERVICES OFFERING 81
    • 7.4.4 KEY DEVELOPMENTS 81
    • 7.4.5 SWOT ANALYSIS 81
    • 7.4.6 KEY STRATEGY 81
  • 7.5 NOVARTIS AG 82
    • 7.5.1 COMPANY OVERVIEW 82
    • 7.5.2 FINANCIAL OVERVIEW 82
    • 7.5.3 PRODUCTS OFFERING 83
    • 7.5.4 KEY DEVELOPMENTS 83
    • 7.5.5 SWOT ANALYSIS 84
    • 7.5.6 KEY STRATEGY 84
  • 7.6 F. HOFFMANN-LA ROCHE AG 85
    • 7.6.1 COMPANY OVERVIEW 85
    • 7.6.2 FINANCIAL OVERVIEW 85
    • 7.6.3 PRODUCTS OFFERING 86
    • 7.6.4 KEY DEVELOPMENTS 86
    • 7.6.5 SWOT ANALYSIS 86
    • 7.6.6 KEY STRATEGY 87
  • 7.7 BAYER AG 88
    • 7.7.1 COMPANY OVERVIEW 88
    • 7.7.2 FINANCIAL OVERVIEW 88
    • 7.7.3 PRODUCTS OFFERING 89
    • 7.7.4 KEY DEVELOPMENTS 89
    • 7.7.5 SWOT ANALYSIS 89
    • 7.7.6 KEY STRATEGY 90
  • 7.8 BRISTOL-MYERS SQUIBB 91
    • 7.8.1 COMPANY OVERVIEW 91
    • 7.8.2 FINANCIAL OVERVIEW 91
    • 7.8.3 PRODUCT OFFERING 92
    • 7.8.4 KEY DEVELOPMENTS 92
    • 7.8.5 SWOT ANALYSIS 92
    • 7.8.6 KEY STRATEGY 92
  • 7.9 EISAI LTD 93
    • 7.9.1 COMPANY OVERVIEW 93
    • 7.9.2 FINANCIAL OVERVIEW 93
    • 7.9.3 PRODUCT OFFERING 93
    • 7.9.4 KEY DEVELOPMENTS 94
    • 7.9.5 SWOT ANALYSIS 94
    • 7.9.6 KEY STRATEGY 94

LIST OF TABLES

  • TABLE 1 LIST OF ASSUMPTIONS 17
  • TABLE 1 PRIMARY INTERVIEWS 19
  • TABLE 2 GLOBAL PONATINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 34
  • TABLE 3 GLOBAL PONATINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 34
  • TABLE 4 GLOBAL BRIGATINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 35
  • TABLE 5 GLOBAL BRIGATINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 35
  • TABLE 6 GLOBAL RUXOLITINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 36
  • TABLE 7 GLOBAL RUXOLITINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 36
  • TABLE 8 GLOBAL ERLOTINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 37
  • TABLE 9 GLOBAL ERLOTINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 37
  • TABLE 10 GLOBAL ALECTINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 38
  • TABLE 11 GLOBAL ALECTINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 38
  • TABLE 12 GLOBAL COBIMETINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 39
  • TABLE 13 GLOBAL COBIMETINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 39
  • TABLE 14 GLOBAL NERATINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 40
  • TABLE 15 GLOBAL NERATINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 40
  • TABLE 16 GLOBAL OSIMERTINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 41
  • TABLE 17 GLOBAL OSIMERTINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 41
  • TABLE 18 GLOBAL ACALABRUTINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 42
  • TABLE 19 GLOBAL ACALABRUTINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 42
  • TABLE 20 GLOBAL BOSUTINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 43
  • TABLE 21 GLOBAL BOSUTINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 43
  • TABLE 22 GLOBAL CRIZOTINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 44
  • TABLE 23 GLOBAL CRIZOTINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 44
  • TABLE 24 GLOBAL AXITINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 45
  • TABLE 25 GLOBAL AXITINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 45
  • TABLE 26 GLOBAL SUNITINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 46
  • TABLE 27 GLOBAL SUNITINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 46
  • TABLE 28 GLOBAL CERITINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 47
  • TABLE 29 GLOBAL CERITINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 47
  • TABLE 30 GLOBAL IMATINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 48
  • TABLE 31 GLOBAL IMATINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 48
  • TABLE 32 GLOBAL LAPATINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 49
  • TABLE 33 GLOBAL LAPATINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 49
  • TABLE 34 GLOBAL AFATINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 50
  • TABLE 35 GLOBAL AFATINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 50
  • TABLE 36 GLOBAL CABOZANTINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 51
  • TABLE 37 GLOBAL CABOZANTINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 51
  • TABLE 38 GLOBAL DASATINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 52
  • TABLE 39 GLOBAL DASATINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 52
  • TABLE 40 GLOBAL IBRUTINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 53
  • TABLE 41 GLOBAL IBRUTINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 53
  • TABLE 42 GLOBAL LENVATINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 54
  • TABLE 43 GLOBAL LENVATINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 54
  • TABLE 44 GLOBAL GEFITINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 55
  • TABLE 45 GLOBAL GEFITINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 55
  • TABLE 46 GLOBAL SORAFENIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 56
  • TABLE 47 GLOBAL SORAFENIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 56
  • TABLE 48 GLOBAL REGORAFENIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 57
  • TABLE 49 GLOBAL REGORAFENIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 57
  • TABLE 50 GLOBAL VEMURAFENIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 58
  • TABLE 51 GLOBAL VEMURAFENIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 58
  • TABLE 52 GLOBAL DABRAFENIB + TRAMETINIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 59
  • TABLE 53 GLOBAL DABRAFENIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 60
  • TABLE 54 GLOBAL TRAMETINIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 60
  • TABLE 55 GLOBAL ENASIDENIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 60
  • TABLE 56 GLOBAL ENASIDENIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 61
  • TABLE 57 GLOBAL VANDETANIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 61
  • TABLE 58 GLOBAL VANDETANIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 61
  • TABLE 59 GLOBAL OLAPARIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 62
  • TABLE 60 GLOBAL OLAPARIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 62
  • TABLE 61 GLOBAL RUCAPARIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 63
  • TABLE 62 GLOBAL RUCAPARIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 63
  • TABLE 63 GLOBAL NIRAPARIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 64
  • TABLE 64 GLOBAL NIRAPARIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 64
  • TABLE 65 GLOBAL IDELALISIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 65
  • TABLE 66 GLOBAL IDELALISIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 65
  • TABLE 67 GLOBAL VISMODEGIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 66
  • TABLE 68 GLOBAL VISMODEGIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 67
  • TABLE 69 GLOBAL PALBOCICLIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 67
  • TABLE 70 GLOBAL PALBOCICLIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 68
  • TABLE 71 GLOBAL RIBOCICLIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 68
  • TABLE 72 GLOBAL RIBOCICLIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 68
  • TABLE 73 GLOBAL ABEMACICLIB MARKET SIZE BY GEOGRAPHY, 2020 TO 2027 (USD MILLION) 69
  • TABLE 74 GLOBAL ABEMACICLIB MARKET VOLUME BY GEOGRAPHY, 2020 TO 2027 (KG) 69

LIST OF FIGURES

  • FIGURE 1 GLOBAL CANCER API MARKET: MARKET STRUCTURE 17
  • FIGURE 2 RESEARCH PROCESS OF MRFR 19
  • FIGURE 3 MARKET DYNAMICS: GLOBAL CANCER API MARKET 24
  • FIGURE 4 VALUE CHAIN: CANCER API MARKET 28
  • FIGURE 5 PORTER'S FIVE FORCES ANALYSIS OF THE GLOBAL CANCER API MARKET 30
  • FIGURE 6 GLOBAL CANCER API MARKET: COMPANY SHARE ANALYSIS, 2020 (%) 71